Boehringer Ingelheim Wins Interchangeable Biosimilar To Humira, Setting Benchmark For Switching Studies
Executive Summary
Cyltezo won’t be available until 2023 due to patent settlement with AbbVie. The second-ever interchangeable biosimilar approved by the US FDA also contains a first: published data from a switch trial.
You may also be interested in...
US Bill Seeks To Eliminate Biosimilar Interchangeability Trial Burden
Sen. Mike Lee, R-UT, has introduced draft legislation in the US that would stop the FDA from requiring biosimilars to conduct ‘unnecessary’ switching studies in order to obtain an interchangeability designation.
US Bill Seeks To Eliminate Biosimilar Interchangeability Trial Burden
Senator Mike Lee has introduced draft legislation in the US that would stop the FDA from requiring biosimilars to conduct “unnecessary” switching studies in order to obtain an interchangeability designation.
Keeping Track: Enhertu, Nubeqa Grow With RTOR; Interchangeable Cimerli And Another Nuplazid CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker